Technological Aspects of Ensuring the Specific Safety of Human Immunoglobulin and Albumin Preparations


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Modern technological approaches to ensuring the specific safety of human immunoglobulin and albumin preparations are analyzed. Introduction into human immunoglobulin preparation technology of donor screening for group- and rhesus-affiliations and chromatographic purification steps to reduce the contents of anti-A and anti-B hemagglutinins and anti-D antibodies are shown to be promising. Technological capabilities for reducing the anticomplementary activity and thrombogenic potential of immunoglobulin preparations and decreasing the contents of prekallikrein activator in human i.v. immunoglobulin and albumin preparations are discussed.

Sobre autores

O. Kornilova

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: chem@folium.ru
Rússia, 8/2 Petrovskii Blvd., Moscow, 127051

M. Krivykh

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: chem@folium.ru
Rússia, 8/2 Petrovskii Blvd., Moscow, 127051

É. Kudasheva

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: chem@folium.ru
Rússia, 8/2 Petrovskii Blvd., Moscow, 127051

I. Borisevich

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: chem@folium.ru
Rússia, 8/2 Petrovskii Blvd., Moscow, 127051


Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2018

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies